Evista Side Effects
Generic name: raloxifene
Note: This document contains side effect information about raloxifene. Some of the dosage forms listed on this page may not apply to the brand name Evista.
Some side effects of Evista may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to raloxifene: oral tablet
Along with its needed effects, raloxifene (the active ingredient contained in Evista) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Stop taking raloxifene and get emergency help immediately if any of the following effects occur:Rare
- Coughing blood
- headache or migraine headache
- loss of or change in speech, coordination, or vision
- pain or numbness in chest, arm, or leg
- shortness of breath (unexplained)
Check with your doctor as soon as possible if any of the following side effects occur while taking raloxifene:More common
- Bloody or cloudy urine
- chest pain
- difficult, burning, or painful urination
- frequent urge to urinate
- infection, including body aches or pain, congestion in throat, cough, dryness or soreness of throat, runny nose, and loss of voice
- leg cramping
- skin rash
- swelling of hands, ankles, or feet
- vaginal itching
- Abdominal pain (severe)
- aching body pains
- congestion in lungs
- decreased vision or other changes in vision
- difficulty in breathing
- loss of appetite
- trouble in swallowing
Some side effects of raloxifene may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Hot flashes, including sudden sweating and feelings of warmth (especially common during the first 6 months of treatment)
- increased white vaginal discharge
- joint or muscle pain
- mental depression
- problems of stomach or intestines, including passing of gas, upset stomach, or vomiting
- swollen joints
- trouble in sleeping
- weight gain (unexplained)
For Healthcare Professionals
Applies to raloxifene: oral tablet
General side effects have included infection (11% to 15%), flu syndrome (15%), and abdominal pain (7%). The most common general side effects were hot flashes (25%) and leg cramps (6%). Hot flashes or flushes tended to occur during the first six months of therapy.
Raloxifene should be discontinued at least 72 hours prior to and during periods of immobilization. Therapy should be resumed only after the patient is fully ambulatory. Patients should be advised to avoid prolonged restrictions of movement during travel. The use of raloxifene (the active ingredient contained in Evista) in women predisposed to thromboembolic disease, such as women with congestive heart failure and malignancy, should be carefully considered.
A large (7,705 women), 3.3 year study reported raloxifene was associated with an increased risk for venous thromboembolism (relative risk 2.1, 95% confidence interval 1.2-3.8)
Cardiovascular side effects have included decreased fibrinogen 12% (versus 2% with estrogen) and Plasminogen Activator Inhibitor-1 2% (versus 9% with estrogen). However, analysis of clinical study data revealed an increased risk of venous thromboembolic events, such as deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis associated with use of raloxifene. The greatest risk of these events occurs within the first four months of treatment.
Chest pain occurred in 4% of raloxifene treated patients.
Genitourinary side effects have included vaginal bleeding (6% versus HRT 64%), vaginitis (4%), UTI (4%), cystitis (3%), leukorrhea (3%), endometrial disorder (uterine-related) (3%), and breast pain (4% versus HRT 38%).
Endometrial proliferation or an increased risk of breast cancer has not been reported with raloxifene (the active ingredient contained in Evista)
Dermatologic side effects have included rash (6%) and sweating (3%).
Gastrointestinal side effects have included nausea (9%), vomiting (3%), dyspepsia (6%), flatulence (2% to 3%), GI disorder (3%), and gastroenteritis (3%).
Metabolic effects of raloxifene (the active ingredient contained in Evista) therapy have resulted in a less positive effect on lipids than conjugated estrogen. High density lipoprotein (HDL) is increased 15% (versus 33% with estrogen). Lipoprotein (a) is decreased 7% (versus 19% with estrogen). Low density lipoprotein (LDL) is decreased 12% (versus 14% with estrogen.
Limited clinical data suggest that women with a history of marked hypertriglyceridemia (>5.6 mmol/L or >500 mg/dL) in response to treatment with oral estrogen or estrogen plus progestin may develop increased levels of triglycerides when treated with raloxifene.
Metabolic side effects have included weight gain (9%) and peripheral edema (3%).
Musculoskeletal side effects have included arthralgia (11%), myalgia (8%), leg cramps (6%), and arthritis (4%).
Nervous system side effects have included depression (6%), insomnia (6%) and fever (3%), hot flashes (25% to 29% versus HRT 3% and placebo 18%), and migraine headaches (2%).
Respiratory side effects have included sinusitis (10%), pharyngitis (8%), cough increased (6%), pneumonia (3%), and laryngitis (2%).
Ocular side effects have included very rare reports of retinal vein occlusion.
More Evista resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.